{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:21:53Z","timestamp":1787840513728,"version":"build-2784847793"},"reference-count":5,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T00:00:00Z","timestamp":1755820800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:p>Vildagliptin, among the most commonly used, OHA, belongs to group dipeptidyl peptidase-4 inhibitors for managing type 2 diabetes mellitus, has recently been associated with bullous pemphigoid, characterized by fluid-filled blisters and erosions on the skin and mucous membranes. We report the series of three cases of bullous pemphigoid in patients of diabetes, who developed bullous pemphigoid after vildagliptin use.<\/jats:p>","DOI":"10.4103\/ijp.ijp_522_24","type":"journal-article","created":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T12:00:38Z","timestamp":1755864038000},"page":"350-352","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["A case series of vildagliptin-associated bullous pemphigoid - Rare side effect"],"prefix":"10.4103","volume":"57","author":[{"given":"Mohit Kumar","family":"Shahi","sequence":"first","affiliation":[{"name":"Department of GMH, King George Medical University, Lucknow, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JV","family":"Ashwin","sequence":"additional","affiliation":[{"name":"Department of GMH, King George Medical University, Lucknow, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astha","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Hind Institute of Medical Sciences, Barabanki, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suvrat","family":"Gupta","sequence":"additional","affiliation":[{"name":"Department of PMR, Hind Institute of Medical Sciences, Barabanki, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Surya","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, King George Medical University, Lucknow, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,8,22]]},"reference":[{"key":"R1-20260421","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1517\/13543784.15.4.431","article-title":"Vildagliptin: An inhibitor of dipeptidyl peptidase-4 with antidiabetic properties","volume":"15","author":"Ahr\u00e9n","year":"2006","journal-title":"Expert Opin Investig Drugs"},{"key":"R2-20260421","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s12016-007-0030-y","article-title":"The pathophysiology of bullous pemphigoid","volume":"33","author":"Kasperkiewicz","year":"2007","journal-title":"Clin Rev Allergy Immunol"},{"key":"R3-20260421","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.jid.2018.10.045","article-title":"Higher frequency of dipeptidyl peptidase-4 inhibitor intake in bullous pemphigoid patients than in the French general population","volume":"139","author":"Plaquevent","year":"2019","journal-title":"J Invest Dermatol"},{"key":"R4-20260421","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1080\/25785826.2020.1787584","article-title":"A case of anti-BP230 antibody-positive bullous pemphigoid receiving DPP-4 inhibitor","volume":"44","author":"Sawada","year":"2021","journal-title":"Immunol Med"},{"key":"R5-20260421","doi-asserted-by":"crossref","first-page":"154","DOI":"10.4239\/wjd.v10.i3.154","article-title":"Crosstalk between gut microbiota and antidiabetic drug action","volume":"10","author":"Kyriachenko","year":"2019","journal-title":"World J Diabetes"}],"container-title":["Indian Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijp.ijp_522_24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:24:16Z","timestamp":1787837056000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijp.ijp_522_24"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,22]]},"references-count":5,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/ijp.ijp_522_24","relation":{},"ISSN":["0253-7613","1998-3751"],"issn-type":[{"value":"0253-7613","type":"print"},{"value":"1998-3751","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,22]]},"assertion":[{"value":"2024-06-18","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-15","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}